@FiercePharma: ImmuCell boosts Q2 sales guidance as inventory management improves. FierceAnimalHealth article | Follow @FiercePharma
@EricPFierce: FDA says China staffer Dr. Lixia Wang was key to negotiating deal for more FDA inspection staff in China. More from FiercePharmaManufacturing | Follow @EricPFierce
@CarlyHFierce: ICYMI yesterday: AstraZeneca grabs $215M for GI drug rights in latest cash-generating deal. Article | Follow @CarlyHFierce
> Daiichi Sankyo has launched its bloodthinner Lixiana in the U.K. Report
> AbbVie ($ABBV) says the European Commission has approved its Imbruvica as the first treatment in the European Union for treating the rare slow-growing blood cancer, Waldenstrom's macroglobulinemia (WM). Release
> Indian drugmaker Cipla has added to its board Samina Vaziralli, niece of Cipla Chairman YK Hamied, as the next generation of the Hamied family gets involved. Report
Medical Device News
@FierceMedDev: ICYMI from FierceDiagnostics: CombiMatrix coasts toward growth with renewed sales push. Report | Follow @FierceMedDev
@StacyALawrence: Go big or go home: A call for FierceMedicalDevices' 2015 Fierce 15 nominations. ICYMI | Follow @StacyALawrence
@EmilyWFierce: Natera joins forces with University College London for lung cancer study. FierceDiagnostics story | Follow @EmilyWFierce
> Smith & Nephew strikes again, bolstering emerging markets with Russian trauma and orthopedics buy. Story
> Xagenic ropes in $15M for point-of-care testing system. Article
> CMS to test new reimbursement system for hip and knee replacements in the U.S. More
Biotech News
@FierceBiotech: 21st Century drug bill triggers a DC dust-up over relaxed development regs. Report | Follow @FierceBiotech
@JohnCFierce: EuroBiotech: KDEV halves portfolio value, U.K. life sci funding hits 10-year high, CF gene therapy on the block. Report | Follow @JohnCFierce
@DamianFierce: ICYMI: Patrick Soon-Shiong tacitly creates another company every time he does anything. NantKwest?! Release | Follow @DamianFierce
> Sanofi cozies up to top-tier labs with new R&D partnering effort. News
> Third Rock's GBT swings for a $115M IPO to push its pill for sickle cell. Article
> Woodford backs ReNeuron's $106M fundraise for cell therapy R&D. Report
And Finally... Naps may improve frustration tolerance, a new study says. More